340B Program Lacks Price Transparency, Federal Watchdogs Tell HELP Committee

Drug Industry Daily
A A
Gauging the 340B drug discount program’s effectiveness requires more price transparency and clearer guidance, expert witnesses told the Senate health committee Tuesday.

To View This Article:

Login

Subscribe To Drug Industry Daily